JP2017515847A5 - - Google Patents

Download PDF

Info

Publication number
JP2017515847A5
JP2017515847A5 JP2016567517A JP2016567517A JP2017515847A5 JP 2017515847 A5 JP2017515847 A5 JP 2017515847A5 JP 2016567517 A JP2016567517 A JP 2016567517A JP 2016567517 A JP2016567517 A JP 2016567517A JP 2017515847 A5 JP2017515847 A5 JP 2017515847A5
Authority
JP
Japan
Prior art keywords
herpes simplex
simplex virus
oncolytic
oncolytic herpes
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016567517A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017515847A (ja
Filing date
Publication date
Priority claimed from GBGB1408297.8A external-priority patent/GB201408297D0/en
Application filed filed Critical
Publication of JP2017515847A publication Critical patent/JP2017515847A/ja
Publication of JP2017515847A5 publication Critical patent/JP2017515847A5/ja
Pending legal-status Critical Current

Links

JP2016567517A 2014-05-12 2015-05-07 がんの治療のための腫瘍溶解性ウイルスおよびオーロラキナーゼ阻害薬 Pending JP2017515847A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1408297.8A GB201408297D0 (en) 2014-05-12 2014-05-12 Treatment of cancer
GB1408297.8 2014-05-12
PCT/GB2015/051347 WO2015173544A1 (en) 2014-05-12 2015-05-07 Oncolytic virus and aurora kinase inhibitor for the treatment of cancer

Publications (2)

Publication Number Publication Date
JP2017515847A JP2017515847A (ja) 2017-06-15
JP2017515847A5 true JP2017515847A5 (enExample) 2018-06-14

Family

ID=51032548

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016567517A Pending JP2017515847A (ja) 2014-05-12 2015-05-07 がんの治療のための腫瘍溶解性ウイルスおよびオーロラキナーゼ阻害薬

Country Status (6)

Country Link
US (1) US20170071991A1 (enExample)
EP (1) EP3142677A1 (enExample)
JP (1) JP2017515847A (enExample)
CN (1) CN106535940A (enExample)
GB (1) GB201408297D0 (enExample)
WO (1) WO2015173544A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102780496B1 (ko) * 2016-07-29 2025-03-11 오하이오 스테이트 이노베이션 파운데이션 종양용해성 바이러스에 의한 PTEN-Long의 발현
US11357776B2 (en) 2016-10-28 2022-06-14 Acetylon Pharmaceuticals, Inc. Pharmaceutical combinations comprising a histone deacetylase inhibitor and an aurora kinase inhibitor and methods of use thereof
JP2020501589A (ja) * 2016-12-23 2020-01-23 ウイルツ・バイオロジクス・リミテッド がんの治療
CN109576231B (zh) * 2017-09-28 2022-03-25 北京康万达医药科技有限公司 分离的重组溶瘤腺病毒、药物组合物及其在治疗肿瘤和/或癌症的药物中的用途
CN109985239B (zh) * 2017-12-29 2024-10-18 广州威溶特医药科技有限公司 极光激酶抑制剂和甲病毒在制备抗肿瘤药物的应用
CN116004567A (zh) * 2022-12-07 2023-04-25 北京大学 极光激酶b基因k202突变及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012122629A1 (en) * 2011-03-11 2012-09-20 Mcmaster University A method of vaccination comprising a histone deacetylase inhibitor
US9249124B2 (en) * 2011-03-30 2016-02-02 H. Lee Moffitt Cancer Center And Research Institute, Inc. Aurora kinase inhibitors and methods of making and using thereof
US9056133B2 (en) * 2011-05-25 2015-06-16 Cti-S.A. Pharmaceutical kit and method for treating cancer

Similar Documents

Publication Publication Date Title
BR112022009571A2 (pt) Uso de inibidor de fak na preparação de um fármaco para tratar tumores que têm mutação nras
ES2762250T3 (es) Tratamiento combinado del cáncer
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
JP2016518387A5 (enExample)
BR112015029918A2 (pt) uso de alta dose de pridopidina para tratar a doença de huntington
AR090885A1 (es) Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple
JP2018109022A5 (enExample)
MX2011013467A (es) Metodo para tratar un paciente que corre el riesgo de desarollar una ulcera asociada a antiinflamatorio no esteroide (aine).
EA201590166A1 (ru) Комбинированная терапия для лечения рассеянного склероза
JP2014525454A5 (enExample)
CN111344398A (zh) 分离的重组溶瘤腺病毒、药物组合物及其在治疗肿瘤和/或癌症的药物中的用途
JP2013522251A (ja) パルボウイルスをhdac阻害剤と併用して使用する癌治療
JP2020521797A5 (enExample)
EA201891931A1 (ru) Новые ингибиторы фосфатидилинозитол-3-киназы гамма
HK1202776A1 (en) Use of laquinimod for treating crohn's disease patients who failed first-line anti-tnf therapy
JP2017531673A5 (enExample)
JP2019515909A5 (enExample)
BR112022003220A2 (pt) Uma composição farmacêutica para tratar câncer usada para um paciente tendo marcador genético específico
Belin et al. An oncolytic vaccinia virus expressing the human sodium iodine symporter prolongs survival and facilitates SPECT/CT imaging in an orthotopic model of malignant pleural mesothelioma
ES3014482T3 (en) Compositions and methods for enhancing production, growth, spread, or oncolytic and immunotherapeutic efficacy of interferon-sensitive viruses
JP2013541583A5 (enExample)
Ady et al. Oncolytic gene therapy with recombinant vaccinia strain GLV-2b372 efficiently kills hepatocellular carcinoma
JP2014534229A5 (enExample)
HRP20231299T1 (hr) Inhibitori pi3k p-delta 110 za uporabu u isporuci virusa u liječenju raka
JP2025517509A5 (enExample)